View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsConformis 配当と自社株買い配当金 基準チェック /06Conformis配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Sep 07+ 1 more updateConformis, Inc.(NasdaqCM:CFMS) dropped from NASDAQ Composite IndexConforMIS, Inc. has been removed from Nasdaq Composite Index.お知らせ • Sep 06Conformis, Inc. Announces Board ChangesConformis, Inc. announced that at the Effective Time and in accordance with the Merger Agreement, the following directors were appointed to the Board: Kurt Jacobus, Greg Anglum and Kenneth Gall.お知らせ • Sep 01Conformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI IndexConformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI IndexReported Earnings • Aug 04Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$1.78 loss per share (improved from US$2.15 loss in 2Q 2022). Revenue: US$13.0m (down 15% from 2Q 2022). Net loss: US$13.0m (loss narrowed 16% from 2Q 2022). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates by 39%. Revenue is forecast to grow 2.2% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$45m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (US$17.1m market cap).お知らせ • Jun 24\Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. (NasdaqCM:CFMS) from shareholders for for $21.4 million.Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. (NasdaqCM:CFMS) from shareholders for $21.4 million on June 22, 2023. Restor3D will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023. In case of termination of the deal, Conformis will be required to pay restor3d a termination fee of $900,000. Conformis' Board of Directors, having determined that the transaction is in the best interests of the company's stockholders, has unanimously approved the transaction. The closing of this transaction is expected by the end of Q3 2023 and is subject to approval by Conformis’ stockholders and other customary closing conditions. UBS Investment Bank is serving as financial advisor and fairness opinion provider to Conformis, and Brian C. O’Fahey of Hogan Lovells US LLP is serving as its legal counsel. William J. Zawrotny of Jones Day is serving as legal counsel to restor3d.お知らせ • May 20+ 1 more updateConformis, Inc. Announces Resignation of Robert S. Howe as Treasurer, Effective June 9, 2023On May 15, 2023, Conformis, Inc. was notified by Robert S. Howe, the Company’s Treasurer, that he will be resigning effective June 9, 2023 (the Departure Date), to accept the Chief Financial Officer role at a larger private-equity backed company not in the orthopedic industry. On May 18, 2023, the Company and Mr. Howe entered into a consulting agreement, permitting him to provide consulting services on a limited basis following his departure as an employee.On May 18, 2023, the Board of Directors of the Company appointed Christine Desrochers, the Company’s current Corporate Controller, as Interim Chief Financial Officer. The appointment is effective as of the Departure Date.Ms. Desrochers has served as the Company’s Corporate Controller since July 2020, after previously serving as the Company’s Assistant Controller since October 2018. From June 2015 to October 2018, she served as Senior Accountant at AgaMatrix. Previously, she served in various senior and staff accounting roles at Kronos, Sonus Networks, GSI Group and Nera Networks. She received an MBA in Accounting from the Sawyer Business School at Suffolk University.お知らせ • May 13Conformis, Inc. Announces Board ChangesOn May 8, 2023, Conformis, Inc. held the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). As of the time of the 2023 Annual Meeting, Michael D. Milligan’s term as a director expired, and the size of the Board was reduced from seven to six directors. In connection therewith, the Board reduced the number of class I director seats from three to two, such that the number of class I, class I and class III director seats is each now two. Carrie Bienkowski, who previously served as a class I director, resigned such class I seat as of the 2023 Annual Meeting, contemporaneous with her election as a class II director to fill the seat previously occupied by Mr. Milligan.お知らせ • May 10Conformis, Inc. Provides Second Quarter Revenue Guidance for the Financial Year Ending December 31, 2023Conformis, Inc. provided second quarter revenue guidance for the financial year ending December 31, 2023. For the period, the company expects second quarter product revenue to be in the range of $11.0 million to $13.0 million.Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$1.32 loss per share (improved from US$2.24 loss in 1Q 2022). Revenue: US$12.8m (down 18% from 1Q 2022). Net loss: US$9.57m (loss narrowed 40% from 1Q 2022). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%. Revenue is forecast to stay flat during the next 2 years compared to a 8.3% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Mar 03Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$6.99 loss per share (further deteriorated from US$0.36 loss in FY 2021). Revenue: US$62.1m (down 38% from FY 2021). Net loss: US$50.5m (loss widened US$48.1m from FY 2021). Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to stay flat during the next 2 years compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.お知らせ • Feb 11Conformis, Inc. Provides Revenue Guidance for the First Quarter of Fiscal 2023Conformis, Inc. provided revenue guidance for the first quarter of fiscal 2023. For the quarter, the company expects product revenue to be in the range of $12 million to $13 million.お知らせ • Jan 24Conformis, Inc. to Report Q4, 2022 Results on Mar 01, 2023Conformis, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 01, 2023Price Target Changed • Nov 16Price target decreased to US$31.25Down from US$35.42, the current price target is an average from 2 analysts. New target price is 2,011% above last closing price of US$1.48. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$8.32 next year compared to a net loss per share of US$0.36 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 04Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: US$0.084 loss per share (further deteriorated from US$0.073 loss in 3Q 2021). Revenue: US$13.8m (down 3.3% from 3Q 2021). Net loss: US$15.2m (loss widened 17% from 3Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.1%. Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Seeking Alpha • Sep 13Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip systemConformis (NASDAQ:CFMS) stock jumped ~17% after hours on Tuesday after the firm received 510(k) clearance from the U.S. Food and Drug Administration for its Actera hip system. Actera uses an advanced tri-taper femur stem design to facilitate a minimally invasive approach similar to direct anterior approach. CFMS will introduce Actera under a limited market release in select U.S. markets, expected to start in the coming months.Reported Earnings • Aug 10Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: US$0.086 loss per share (down from US$0.21 profit in 2Q 2021). Revenue: US$15.3m (down 73% from 2Q 2021). Net loss: US$15.5m (down 141% from profit in 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 6.3%, compared to a 6.2% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 01Conformis signs agreement with Vizient for personalized orthopedic implantsMedical device firm Conformis (NASDAQ:CFMS) said it had entered into a multi-year agreement with Vizient to offer its personalized orthopedic implants. (CFMS) is trading 5.9% higher after the bell. The agreement gives access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Mar 09Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$65.6m to US$64.9m. Losses expected to increase from US$0.24 per share to US$0.28. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$2.00 unchanged from last update. Share price rose 7.9% to US$0.71 over the past week.Reported Earnings • Mar 04Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.014 loss per share (up from US$0.34 loss in FY 2020). Revenue: US$99.9m (up 45% from FY 2020). Net loss: US$2.41m (loss narrowed 90% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 60%. Over the next year, revenue is expected to shrink by 34% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.分析記事 • Jan 11Investors Will Want Conformis' (NASDAQ:CFMS) Growth In ROCE To PersistIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...分析記事 • Dec 21We Think Conformis (NASDAQ:CFMS) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 11What Does Conformis, Inc.'s (NASDAQ:CFMS) Share Price Indicate?Conformis, Inc. ( NASDAQ:CFMS ), is not the largest company out there, but it received a lot of attention from a...Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.073 loss per share (vs US$0.087 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$14.3m (down 12% from 3Q 2020). Net loss: US$13.0m (loss widened 110% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Nov 05CEO, President & Director recently sold US$60k worth of stockOn the 2nd of November, Mark Augusti sold around 50k shares on-market at roughly US$1.20 per share. This was the largest sale by an insider in the last 3 months. Mark has been a seller over the last 12 months, reducing personal holdings by US$180k.Price Target Changed • Sep 22Price target decreased to US$2.17Down from US$2.50, the current price target is an average from 4 analysts. New target price is 41% above last closing price of US$1.54. Stock is up 79% over the past year.Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$1.82, the stock trades at a trailing P/E ratio of 24.7x. Average forward P/E is 43x in the Medical Equipment industry in the US. Total returns to shareholders of 47% over the past three years.分析記事 • Sep 16Is Conformis (NASDAQ:CFMS) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 04Conformis: Emerging Surgical Implant DeveloperConformis is a small company developing knee and hip replacement implants. They have recent collaboration deals with major players. The company has a decent cash balance, but revenue growth is impacted by the pandemic.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$1.61, the stock trades at a trailing P/E ratio of 13.5x. Average forward P/E is 43x in the Medical Equipment industry in the US. Total returns to shareholders of 32% over the past three years.分析記事 • Aug 11Shareholders Shouldn’t Be Too Comfortable With Conformis' (NASDAQ:CFMS) Strong EarningsStrong earnings weren't enough to please Conformis, Inc.'s ( NASDAQ:CFMS ) shareholders over the last week. Our...Major Estimate Revision • Aug 11Consensus revenue estimates increase to US$95.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$84.4m to US$95.8m. Now expected to report a profit of US$0.0077 instead of losses of -US$0.18 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$2.33 unchanged from last update. Share price fell 19% to US$1.33 over the past week.Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$1.33, the stock trades at a trailing P/E ratio of 11.1x. Average forward P/E is 41x in the Medical Equipment industry in the US. Total returns to shareholders of 43% over the past three years.分析記事 • Aug 10Party Time: Brokers Just Made Major Increases To Their Conformis, Inc. (NASDAQ:CFMS) Earnings ForecastsCelebrations may be in order for Conformis, Inc. ( NASDAQ:CFMS ) shareholders, with the analysts delivering a...Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.031 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$56.3m (up 189% from 2Q 2020). Net income: US$38.0m (up US$40.2m from 2Q 2020). Profit margin: 68% (up from net loss in 2Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.分析記事 • May 18Increases to Conformis, Inc.'s (NASDAQ:CFMS) CEO Compensation Might Cool off for nowIn the past three years, the share price of Conformis, Inc. ( NASDAQ:CFMS ) has struggled to grow and now shareholders...Major Estimate Revision • May 13Consensus revenue estimates increase to US$90.7mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$68.5m to US$90.7m. Forecast losses expected to reduce from -US$0.21 to -US$0.13 per share. Medical Equipment industry in the US expected to see average net income growth of 28% next year. Consensus price target of US$2.33 unchanged from last update. Share price was steady at US$0.82 over the past week.分析記事 • May 11Analysts Just Shipped An Incredible Upgrade To Their Conformis, Inc. (NASDAQ:CFMS) EstimatesConformis, Inc. ( NASDAQ:CFMS ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • May 08Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • May 07First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.14 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$13.8m (down 16% from 1Q 2020). Net loss: US$11.5m (loss widened 23% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Major Estimate Revision • Mar 11Analysts update estimatesThe 2021 consensus revenue estimate was lowered from US$77.5m to US$68.5m. Earnings per share (EPS) saw an improvement, with analysts raising their estimates from -US$0.29 to -US$0.20 for the same period. The Medical Equipment industry in the US is expected to see an average net income growth of 21% next year. The consensus price target of US$2.33 was unchanged from the last update. Share price is down by 11% to US$0.97 over the past week.Reported Earnings • Mar 05Full year 2020 earnings released: US$0.34 loss per share (vs US$0.44 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$68.8m (down 11% from FY 2019). Net loss: US$24.3m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 05Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 13%, compared to a 21% growth forecast for the Medical Equipment industry in the US.分析記事 • Jan 16Is Conformis (NASDAQ:CFMS) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is New 90 Day High Low • Jan 07New 90-day high: US$0.81The company is up 6.0% from its price of US$0.76 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 6.5%, compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.087 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: US$16.1m (down 6.8% from 3Q 2019). Net loss: US$6.18m (loss narrowed 29% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 05New 90-day low: US$0.65The company is down 8.0% from its price of US$0.71 on 07 August 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 25New 90-day high: US$0.88The company is up 8.0% from its price of US$0.81 on 26 June 2020. The American market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.決済の安定と成長配当データの取得安定した配当: CFMSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CFMSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Conformis 配当利回り対市場CFMS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CFMS)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Medical Equipment)2.2%アナリスト予想 (CFMS) (最長3年)n/a注目すべき配当: CFMSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CFMSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CFMSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CFMSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/09/06 07:09終値2023/09/01 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Conformis, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Gregory ChodaczekB. Riley Securities, Inc.Michael GormanBTIGKyle RoseCanaccord Genuity6 その他のアナリストを表示
お知らせ • Sep 07+ 1 more updateConformis, Inc.(NasdaqCM:CFMS) dropped from NASDAQ Composite IndexConforMIS, Inc. has been removed from Nasdaq Composite Index.
お知らせ • Sep 06Conformis, Inc. Announces Board ChangesConformis, Inc. announced that at the Effective Time and in accordance with the Merger Agreement, the following directors were appointed to the Board: Kurt Jacobus, Greg Anglum and Kenneth Gall.
お知らせ • Sep 01Conformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI IndexConformis, Inc.(NasdaqCM:CFMS) dropped from S&P TMI Index
Reported Earnings • Aug 04Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$1.78 loss per share (improved from US$2.15 loss in 2Q 2022). Revenue: US$13.0m (down 15% from 2Q 2022). Net loss: US$13.0m (loss narrowed 16% from 2Q 2022). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates by 39%. Revenue is forecast to grow 2.2% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$45m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (US$17.1m market cap).
お知らせ • Jun 24\Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. (NasdaqCM:CFMS) from shareholders for for $21.4 million.Restor3D, Inc. entered into a definitive merger agreement to acquire Conformis, Inc. (NasdaqCM:CFMS) from shareholders for $21.4 million on June 22, 2023. Restor3D will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023. In case of termination of the deal, Conformis will be required to pay restor3d a termination fee of $900,000. Conformis' Board of Directors, having determined that the transaction is in the best interests of the company's stockholders, has unanimously approved the transaction. The closing of this transaction is expected by the end of Q3 2023 and is subject to approval by Conformis’ stockholders and other customary closing conditions. UBS Investment Bank is serving as financial advisor and fairness opinion provider to Conformis, and Brian C. O’Fahey of Hogan Lovells US LLP is serving as its legal counsel. William J. Zawrotny of Jones Day is serving as legal counsel to restor3d.
お知らせ • May 20+ 1 more updateConformis, Inc. Announces Resignation of Robert S. Howe as Treasurer, Effective June 9, 2023On May 15, 2023, Conformis, Inc. was notified by Robert S. Howe, the Company’s Treasurer, that he will be resigning effective June 9, 2023 (the Departure Date), to accept the Chief Financial Officer role at a larger private-equity backed company not in the orthopedic industry. On May 18, 2023, the Company and Mr. Howe entered into a consulting agreement, permitting him to provide consulting services on a limited basis following his departure as an employee.On May 18, 2023, the Board of Directors of the Company appointed Christine Desrochers, the Company’s current Corporate Controller, as Interim Chief Financial Officer. The appointment is effective as of the Departure Date.Ms. Desrochers has served as the Company’s Corporate Controller since July 2020, after previously serving as the Company’s Assistant Controller since October 2018. From June 2015 to October 2018, she served as Senior Accountant at AgaMatrix. Previously, she served in various senior and staff accounting roles at Kronos, Sonus Networks, GSI Group and Nera Networks. She received an MBA in Accounting from the Sawyer Business School at Suffolk University.
お知らせ • May 13Conformis, Inc. Announces Board ChangesOn May 8, 2023, Conformis, Inc. held the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). As of the time of the 2023 Annual Meeting, Michael D. Milligan’s term as a director expired, and the size of the Board was reduced from seven to six directors. In connection therewith, the Board reduced the number of class I director seats from three to two, such that the number of class I, class I and class III director seats is each now two. Carrie Bienkowski, who previously served as a class I director, resigned such class I seat as of the 2023 Annual Meeting, contemporaneous with her election as a class II director to fill the seat previously occupied by Mr. Milligan.
お知らせ • May 10Conformis, Inc. Provides Second Quarter Revenue Guidance for the Financial Year Ending December 31, 2023Conformis, Inc. provided second quarter revenue guidance for the financial year ending December 31, 2023. For the period, the company expects second quarter product revenue to be in the range of $11.0 million to $13.0 million.
Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$1.32 loss per share (improved from US$2.24 loss in 1Q 2022). Revenue: US$12.8m (down 18% from 1Q 2022). Net loss: US$9.57m (loss narrowed 40% from 1Q 2022). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%. Revenue is forecast to stay flat during the next 2 years compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Mar 03Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$6.99 loss per share (further deteriorated from US$0.36 loss in FY 2021). Revenue: US$62.1m (down 38% from FY 2021). Net loss: US$50.5m (loss widened US$48.1m from FY 2021). Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to stay flat during the next 2 years compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
お知らせ • Feb 11Conformis, Inc. Provides Revenue Guidance for the First Quarter of Fiscal 2023Conformis, Inc. provided revenue guidance for the first quarter of fiscal 2023. For the quarter, the company expects product revenue to be in the range of $12 million to $13 million.
お知らせ • Jan 24Conformis, Inc. to Report Q4, 2022 Results on Mar 01, 2023Conformis, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 01, 2023
Price Target Changed • Nov 16Price target decreased to US$31.25Down from US$35.42, the current price target is an average from 2 analysts. New target price is 2,011% above last closing price of US$1.48. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$8.32 next year compared to a net loss per share of US$0.36 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 04Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: US$0.084 loss per share (further deteriorated from US$0.073 loss in 3Q 2021). Revenue: US$13.8m (down 3.3% from 3Q 2021). Net loss: US$15.2m (loss widened 17% from 3Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.1%. Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Seeking Alpha • Sep 13Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip systemConformis (NASDAQ:CFMS) stock jumped ~17% after hours on Tuesday after the firm received 510(k) clearance from the U.S. Food and Drug Administration for its Actera hip system. Actera uses an advanced tri-taper femur stem design to facilitate a minimally invasive approach similar to direct anterior approach. CFMS will introduce Actera under a limited market release in select U.S. markets, expected to start in the coming months.
Reported Earnings • Aug 10Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: US$0.086 loss per share (down from US$0.21 profit in 2Q 2021). Revenue: US$15.3m (down 73% from 2Q 2021). Net loss: US$15.5m (down 141% from profit in 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 6.3%, compared to a 6.2% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 01Conformis signs agreement with Vizient for personalized orthopedic implantsMedical device firm Conformis (NASDAQ:CFMS) said it had entered into a multi-year agreement with Vizient to offer its personalized orthopedic implants. (CFMS) is trading 5.9% higher after the bell. The agreement gives access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. CEO, President & Director Mark Augusti was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Mar 09Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$65.6m to US$64.9m. Losses expected to increase from US$0.24 per share to US$0.28. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$2.00 unchanged from last update. Share price rose 7.9% to US$0.71 over the past week.
Reported Earnings • Mar 04Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.014 loss per share (up from US$0.34 loss in FY 2020). Revenue: US$99.9m (up 45% from FY 2020). Net loss: US$2.41m (loss narrowed 90% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 60%. Over the next year, revenue is expected to shrink by 34% compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
分析記事 • Jan 11Investors Will Want Conformis' (NASDAQ:CFMS) Growth In ROCE To PersistIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
分析記事 • Dec 21We Think Conformis (NASDAQ:CFMS) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 11What Does Conformis, Inc.'s (NASDAQ:CFMS) Share Price Indicate?Conformis, Inc. ( NASDAQ:CFMS ), is not the largest company out there, but it received a lot of attention from a...
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.073 loss per share (vs US$0.087 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$14.3m (down 12% from 3Q 2020). Net loss: US$13.0m (loss widened 110% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Nov 05CEO, President & Director recently sold US$60k worth of stockOn the 2nd of November, Mark Augusti sold around 50k shares on-market at roughly US$1.20 per share. This was the largest sale by an insider in the last 3 months. Mark has been a seller over the last 12 months, reducing personal holdings by US$180k.
Price Target Changed • Sep 22Price target decreased to US$2.17Down from US$2.50, the current price target is an average from 4 analysts. New target price is 41% above last closing price of US$1.54. Stock is up 79% over the past year.
Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$1.82, the stock trades at a trailing P/E ratio of 24.7x. Average forward P/E is 43x in the Medical Equipment industry in the US. Total returns to shareholders of 47% over the past three years.
分析記事 • Sep 16Is Conformis (NASDAQ:CFMS) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Sep 04Conformis: Emerging Surgical Implant DeveloperConformis is a small company developing knee and hip replacement implants. They have recent collaboration deals with major players. The company has a decent cash balance, but revenue growth is impacted by the pandemic.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$1.61, the stock trades at a trailing P/E ratio of 13.5x. Average forward P/E is 43x in the Medical Equipment industry in the US. Total returns to shareholders of 32% over the past three years.
分析記事 • Aug 11Shareholders Shouldn’t Be Too Comfortable With Conformis' (NASDAQ:CFMS) Strong EarningsStrong earnings weren't enough to please Conformis, Inc.'s ( NASDAQ:CFMS ) shareholders over the last week. Our...
Major Estimate Revision • Aug 11Consensus revenue estimates increase to US$95.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$84.4m to US$95.8m. Now expected to report a profit of US$0.0077 instead of losses of -US$0.18 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$2.33 unchanged from last update. Share price fell 19% to US$1.33 over the past week.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$1.33, the stock trades at a trailing P/E ratio of 11.1x. Average forward P/E is 41x in the Medical Equipment industry in the US. Total returns to shareholders of 43% over the past three years.
分析記事 • Aug 10Party Time: Brokers Just Made Major Increases To Their Conformis, Inc. (NASDAQ:CFMS) Earnings ForecastsCelebrations may be in order for Conformis, Inc. ( NASDAQ:CFMS ) shareholders, with the analysts delivering a...
Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.031 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$56.3m (up 189% from 2Q 2020). Net income: US$38.0m (up US$40.2m from 2Q 2020). Profit margin: 68% (up from net loss in 2Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
分析記事 • May 18Increases to Conformis, Inc.'s (NASDAQ:CFMS) CEO Compensation Might Cool off for nowIn the past three years, the share price of Conformis, Inc. ( NASDAQ:CFMS ) has struggled to grow and now shareholders...
Major Estimate Revision • May 13Consensus revenue estimates increase to US$90.7mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$68.5m to US$90.7m. Forecast losses expected to reduce from -US$0.21 to -US$0.13 per share. Medical Equipment industry in the US expected to see average net income growth of 28% next year. Consensus price target of US$2.33 unchanged from last update. Share price was steady at US$0.82 over the past week.
分析記事 • May 11Analysts Just Shipped An Incredible Upgrade To Their Conformis, Inc. (NASDAQ:CFMS) EstimatesConformis, Inc. ( NASDAQ:CFMS ) shareholders will have a reason to smile today, with the analysts making substantial...
分析記事 • May 08Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • May 07First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.14 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$13.8m (down 16% from 1Q 2020). Net loss: US$11.5m (loss widened 23% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Mar 11Analysts update estimatesThe 2021 consensus revenue estimate was lowered from US$77.5m to US$68.5m. Earnings per share (EPS) saw an improvement, with analysts raising their estimates from -US$0.29 to -US$0.20 for the same period. The Medical Equipment industry in the US is expected to see an average net income growth of 21% next year. The consensus price target of US$2.33 was unchanged from the last update. Share price is down by 11% to US$0.97 over the past week.
Reported Earnings • Mar 05Full year 2020 earnings released: US$0.34 loss per share (vs US$0.44 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$68.8m (down 11% from FY 2019). Net loss: US$24.3m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 05Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 13%, compared to a 21% growth forecast for the Medical Equipment industry in the US.
分析記事 • Jan 16Is Conformis (NASDAQ:CFMS) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Is New 90 Day High Low • Jan 07New 90-day high: US$0.81The company is up 6.0% from its price of US$0.76 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 6.5%, compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.087 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: US$16.1m (down 6.8% from 3Q 2019). Net loss: US$6.18m (loss narrowed 29% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 05New 90-day low: US$0.65The company is down 8.0% from its price of US$0.71 on 07 August 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 25New 90-day high: US$0.88The company is up 8.0% from its price of US$0.81 on 26 June 2020. The American market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.